Photodynamic therapy of cancer: An update

CA Cancer Journal for Clinicians

Volumn 61, Issue 4, 2011, Pages 250-281

  Agostinis, Patrizia ^a   Berg, Kristian ^b   Cengel, Keith A ^c   Foster, Thomas H ^d   Girotti, Albert W ^e   Gollnick, Sandra O ^f   Hahn, Stephen M ^c   Hamblin, Michael R ^g,i   Juzeniene, Asta ^b   Kessel, David ^b   Korbelik, Mladen ^j   Moan, Johan ^b,j   Mroz, Pawel ^g,h   Nowis, Dominika ^k   Piette, Jacques ^l   Wilson, Brian C ^m   Golab, Jakub ^k,n  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

^k MEDICAL UNIVERSITY OF WARSAW   (Poland)

^l UNIVERSITY OF LIÈGE   (Belgium)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ INSTITUTE OF PHYSICAL CHEMISTRY   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 HEXYLOXYETHYL) 2 DEVINYL PYROPHEOPHORBIDE A; ALPHA TOCOPHEROL; AMINO ACID; AMINOLEVULINIC ACID; ASCORBIC ACID; CATALASE; CHLORIN E6 POLYVINYLPYRROLIDONE; CISPLATIN; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LUTETIUM TEXAPHYRIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OXYGEN; PADOPORFIN; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE SILICON; ROSTAPORFIN; SUPEROXIDE DISMUTASE; TALAPORFIN; TEMOPORFIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN; VINCRISTINE;

ADAPTIVE IMMUNITY; ARTICLE; BILE DUCT CANCER; BLADDER CANCER; BLOOD VESSEL INJURY; BLUE LIGHT; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROTECTION; CLINICAL TRIAL (TOPIC); COLON CANCER; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG POTENTIATION; ESOPHAGUS CANCER; ESTHETICS; EYE CANCER; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; INFRARED RADIATION; INNATE IMMUNITY; LIGHT EMITTING DIODE; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MICROVASCULATURE; MORBIDITY; NASOPHARYNX CANCER; NASOPHARYNX CARCINOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; QUALITY OF LIFE; RED LIGHT; SARCOMA; SKIN CANCER; TREATMENT OUTCOME;

HUMANS; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 80051580475     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20114     Document Type: Article

References (290)

1. Bergh J. Quo vadis with targeted drugs in the 21st century? J Clin Oncol. 2009;27: 2-5.
2. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101:1044-1048.
3. Hampton T. Targeted cancer therapies lagging: better trial design could boost success rate. JAMA. 2006;296:1951-1952. (Pubitemid 44631430)
4. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905. (Pubitemid 28304157)
5. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380-387. (Pubitemid 37328858)
6. Allison RR, Sibata CH. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn Ther. 2010;7:61-75.
7. Chen B, Roskams T, de Witte PA. Antivascular tumor eradication by hypericinmediated photodynamic therapy. Photochem Photobiol. 2002;76:509-513.
8. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta. 2010;1805:53-71.
9. Ascencio M, Collinet P, Farine MO, Mordon S. Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy. Lasers Surg Med. 2008;40: 332-341. (Pubitemid 351920383)
10. De Rosa FS, Bentley MV. Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives. Pharm Res. 2000;17:1447-1455. (Pubitemid 32218725)
11. Hamblin MR, Newman EL. On the mechanism of the tumour-localising effect in photodynamic therapy. J Photochem Photobiol B. 1994;23:3-8. (Pubitemid 24119067)
12. Iyer AK, Greish K, Seki T, et al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug Target. 2007;15:496-506. (Pubitemid 47209050)
13. Kessel D. The role of low-density lipoprotein in the biodistribution of photosensi-tizing agents. J Photochem Photobiol B. 1992;14:261-262.
14. Sibani SA, McCarron PA, Woolfson AD, Donnelly RF. Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms. Expert Opin Drug Deliv. 2008;5:1241-1254.
15. Juzeniene A, Nielsen KP, Moan J. Biophysical aspects of photodynamic therapy. J Environ Pathol Toxicol Oncol. 2006;25: 7-28. (Pubitemid 43341232)
16. Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med. 2006;38: 489-493.
17. Brancaleon L, Moseley H. Laser and nonlaser light sources for photodynamic therapy. Lasers Med Sci. 2002;17:173-186.
18. Juzeniene A, Juzenas P, Ma LW, Iani V, Moan J. Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy. Lasers Med Sci. 2004;19: 139-149. (Pubitemid 40174126)
19. Szeimies RM, Morton CA, Sidoroff A, Braathen LR. Photodynamic therapy for non-melanoma skin cancer. Acta Derm Venereol. 2005;85:483-490. (Pubitemid 43087284)
20. Beyer W. Systems for light application and dosimetry in photodynamic therapy. J Photochem Photobiol B. 1996;36: 153-156. (Pubitemid 27011260)
21. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol. 2008;53: R61-R109. (Pubitemid 351570924)
22. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci. 2009; 24:259-268.
23. Foote CS. Mechanisms of photosensitized oxidation. There are several different types of photosensitized oxidation which may be important in biological systems. Science. 1968;162:963-970.
24. Dysart JS, Patterson MS. Characterization of Photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of MLL cells in vitro. Phys Med Biol. 2005;50:2597-2616. (Pubitemid 40770642)
25. Moan J, Berg K, Kvam E, et al. Intracellular localization of photosensitizers. Ciba Found Symp. 1989;146:95-107; discussion 107-111.
26. Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta. 2007;1776: 86-107. (Pubitemid 47332075)
27. Kessel D, Castelli M. Evidence that bcl-2 is the target of three photosensitizers that induce a rapid apoptotic response. Photochem Photobiol. 2001;74:318-322.
28. Xue LY, Chiu SM, Oleinick NL. Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Oncogene. 2001;20:3420-3427. (Pubitemid 32588990)
29. Usuda J, Chiu SM, Murphy ES, Lam M, Nieminen AL, Oleinick NL. Domaindependent photodamage to Bcl-2. A membrane anchorage region is needed to form the target of phthalocyanine photosensitization. J Biol Chem. 2003;278:2021-2029. (Pubitemid 36801445)
30. Berg K, Moan J. Lysosomes as photochemical targets. Int J Cancer. 1994;59:814-822.
31. Reiners JJ Jr, Caruso JA, Mathieu P, Chelladurai B, Yin XM, Kessel D. Release of cytochrome c and activation of procaspase-9 following lysosomal photodamage involves Bid cleavage. Cell Death Differ. 2002;9:934-944. (Pubitemid 35033432)
32. Kessel D. Relocalization of cationic porphyrins during photodynamic therapy. Photochem Photobiol Sci. 2002;1:837-840. (Pubitemid 37069807)
33. Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N, Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med. 2008;8:207-220. (Pubitemid 351982539)
34. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev. 2006;20:1-15. (Pubitemid 43042662)
35. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652-658. (Pubitemid 40488558)
36. Buytaert E, Callewaert G, Vandenheede JR, Agostinis P. Deficiency in apoptotic effectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy. 2006;2:238-240. (Pubitemid 44030895)
37. Reiners JJ Jr, Agostinis P, Berg K, Oleinick NL, Kessel D. Assessing autophagy in the context of photodynamic therapy. Autophagy. 2010;6:7-18.
38. Dewaele M, Maes H, Agostinis P. ROSmediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy. 2010;6:838-854.
39. Sattler UG, Mueller-Klieser W. The antioxidant capacity of tumour glycolysis. Int J Radiat Biol. 2009;85:963-971.
40. Frank J, Flaccus A, Schwarz C, Lambert C, Biesalski HK. Ascorbic acid suppresses cell death in rat DS-sarcoma cancer cells induced by 5-aminolevulinic acid-based photodynamic therapy. Free Radic Biol Med. 2006;40:827-836. (Pubitemid 43327317)
41. Golab J, Nowis D, Skrzycki M, et al. Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003;278:407-414. (Pubitemid 36043590)
42. Hadjur C, Richard MJ, Parat MO, Jardon P, Favier A. Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Photochem Photobiol. 1996;64:375-381. (Pubitemid 26351267)
43. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002;1: 1-21. (Pubitemid 37069701)
44. Matroule JY, Bonizzi G, Morliere P, et al. Pyropheophorbide-a methyl estermediated photosensitization activates transcription factor NF-kappaB through the interleukin-1 receptor-dependent signaling pathway. J Biol Chem. 1999;274: 2988-3000. (Pubitemid 29075386)
45. Wang HP, Hanlon JG, Rainbow AJ, Espiritu M, Singh G. Up-regulation of Hsp27 plays a role in the resistance of human colon carcinoma HT29 cells to photooxidative stress. Photochem Photobiol. 2002;76: 98-104.
46. Hanlon JG, Adams K, Rainbow AJ, Gupta RS, Singh G. Induction of Hsp60 by Photofrin-mediated photodynamic therapy. J Photochem Photobiol B. 2001;64:55-61. (Pubitemid 33064729)
47. Nonaka M, Ikeda H, Inokuchi T. Inhibitory effect of heat shock protein 70 on apoptosis induced by photodynamic therapy in vitro. Photochem Photobiol. 2004;79: 94-98.
48. Szokalska A, Makowski M, Nowis D, et al. Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res. 2009;69:4235-4243.
49. Castellani A, Pace GP, Concioli M. Photodynamic effect of haematoporphyrin on blood microcirculation. J Pathol Bacteriol. 1963;86:99-102.
50. Star WM, Marijnissen HP, van den Berg-Blok AE, Versteeg JA, Franken KA, Reinhold HS. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 1986;46: 2532-2540. (Pubitemid 16120726)
51. Bhuvaneswari R, Gan YY, Soo KC, Olivo M. The effect of photodynamic therapy on tumor angiogenesis. Cell Mol Life Sci. 2009;66:2275-2283.
52. Tseng MT, Reed MW, Ackermann DM, Schuschke DA, Wieman TJ, Miller FN. Photodynamic therapy induced ultrastructural alterations in microvasculature of the rat cremaster muscle. Photochem Photobiol. 1988;48:675-681.
53. Henderson BW, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 1985;45:572-576. (Pubitemid 15161049)
54. Henderson BW, Fingar VH. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem Photobiol. 1989;49: 299-304.
55. Gomer CJ, Rucker N, Murphree AL. Differential cell photosensitivity following porphyrin photodynamic therapy. Cancer Res. 1988;48:4539-4542.
56. West CM, West DC, Kumar S, Moore JV. A comparison of the sensitivity to photodynamic treatment of endothelial and tumour cells in different proliferative states. Int J Radiat Biol. 1990;58:145-156. (Pubitemid 20216900)
57. Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res. 1992;52:4914-4921.
58. Chen B, Pogue BW, Luna JM, Hardman RL, Hoopes PJ, Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res. 2006;12(3 pt 1):917-923. (Pubitemid 43259874)
59. Mitra S, Foster TH. In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-Laspartylchlorin-e6. Neoplasia. 2008;10: 429-438. (Pubitemid 351657385)
60. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 2003;63: 8126-8131. (Pubitemid 37549458)
61. Hirschberg H, Uzal FA, Chighvinadze D, Zhang MJ, Peng Q, Madsen SJ. Disruption of the blood-brain barrier following ALAmediated photodynamic therapy. Lasers Surg Med. 2008;40:535-542.
62. Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg Med. 2006;38:500-508.
63. Krosl G, Korbelik M, Dougherty GJ. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br J Cancer. 1995; 71:549-555.
64. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 1999;137:91-98. (Pubitemid 29179500)
65. de Vree WJ, Essers MC, Koster JF, Sluiter W. Role of interleukin 1 and granulocyte colony-stimulating factor in photofrinbased photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res. 1997; 57:2555-2558. (Pubitemid 27283755)
66. Kousis PC, Henderson BW, Maier PG, Gollnick SO. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 2007;67:10501-10510. (Pubitemid 350070826)
67. Korbelik M, Cecic I. Mechanism of tumor destruction by photodynamic therapy. In: Nalwa HS, ed. Handbook of Photochemistry and Photobiology. Stevenson Ranch, CA: American Scientific Publishers; 2003:39-77.
68. Sun J, Cecic I, Parkins CS, Korbelik M. Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours. Photochem Photobiol Sci. 2002;1:690-695. (Pubitemid 37069785)
69. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 2003;88:1772-1779. (Pubitemid 36760423)
70. Hunt DW, Levy JG. Immunomodulatory aspects of photodynamic therapy. Expert Opin Investig Drugs. 1998;7:57-64. (Pubitemid 28025484)
71. Yusuf N, Katiyar SK, Elmets CA. The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4\+ and CD8\+ T cells and can be adoptively transferred to naive recipients. Photochem Photobiol. 2008;84: 366-370. (Pubitemid 351421387)
72. Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res. 1996; 56:5647-5652. (Pubitemid 26422167)
73. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001;61: 192-196. (Pubitemid 32095717)
74. Maeurer MJ, Gollin SM, Storkus WJ, et al. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome. Clin Cancer Res. 1996;2: 641-652. (Pubitemid 26133466)
75. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation. 2004;77:115-121. (Pubitemid 38116882)
76. Canti GL, Lattuada D, Nicolin A, Taroni P, Valentini G, Cubeddu R. Immunopharmacology studies on photosensitizers used in photodynamic therapy. Proc SPIE. 1994; 2078:268-275.
77. Korbelik M, Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 1999;59:1941-1946. (Pubitemid 29186169)
78. Thong PS, Ong KW, Goh NS, et al. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol. 2007;8:950-952. (Pubitemid 47488070)
79. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO. Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res. 2009;15:4460-4466.
80. Kabingu E, Vaughan L, Owczarczak B, Ramsey KD, Gollnick SO. CD8\+ T cellmediated control of distant tumours following local photodynamic therapy is independent of CD4\+ T cells and dependent on natural killer cells. Br J Cancer. 2007; 96:1839-1848. (Pubitemid 46912014)
81. Henderson BW, Gollnick SO, Snyder JW, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004;64: 2120-2126. (Pubitemid 38339462)
82. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol. 2004;16: 21-25.
83. Sur BW, Nguyen P, Sun CH, Tromberg BJ, Nelson EL. Immunophototherapy using PDT combined with rapid intratumoral dendritic cell injection. Photochem Photobiol. 2008;84:1257-1264.
84. Castellino F, Germain RN. Cooperation between CD4\+ and CD8\+ T cells: when, where, and how. Annu Rev Immunol. 2006;24:519-540.
85. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 2002;62:1604-1608. (Pubitemid 34408477)
86. Korbelik M, Sun J. Photodynamic therapygenerated vaccine for cancer therapy. Cancer Immunol Immunother. 2006;55: 900-909. (Pubitemid 43673579)
87. Korbelik M, Merchant S, Huang N. Exploitation of immune response-eliciting properties of hypocrellin photosensitizer SL052-based photodynamic therapy for eradication of malignant tumors. Photochem Photobiol. 2009;85:1418-1424.
88. Jalili A, Makowski M, Switaj T, et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res. 2004;10: 4498-4508. (Pubitemid 38878894)
89. Henderson BW, Gollnick SO. Mechanistic principles of photodynamic therapy. In: Vo-Dinh T, ed. Biomedical Photonics Handbook. Boca Raton, FL: CRC Press; 2003:36.1-36.27.
90. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998;150(5 suppl):S146-S156. (Pubitemid 28519059)
91. Gollnick SO, Owczarczak B, Maier P. Photodynamic therapy and anti-tumor immunity. Lasers Surg Med. 2006;38:509-515.
92. Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res. 2005;65:1018-1026. (Pubitemid 40216464)
93. Korbelik M, Stott B, Sun J. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression. Br J Cancer. 2007;97:1381-1387. (Pubitemid 350114797)
94. Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol. 2002; 270:169-184. (Pubitemid 35448160)
95. Gomer CJ, Ryter SW, Ferrario A, Rucker N, Wong S, Fisher AM. Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res. 1996;56:2355-2360. (Pubitemid 26155168)
96. Gollnick SO, Kabingu E, Kousis PC, Henderson BW. Stimulation of the host immune response by photodynamic therapy (PDT). Proc SPIE. 2004;5319:60-70.
97. Stott B, Korbelik M. Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy. Cancer Immunol Immunother. 2007;56:649-658. (Pubitemid 46348734)
98. Gomer CJ, Ferrario A, Murphree AL. The effect of localized porphyrin photodynamic therapy on the induction of tumour metastasis. Br J Cancer. 1987;56:27-32. (Pubitemid 17097693)
99. van Duijnhoven FH, Aalbers RI, Rovers JP, Terpstra OT, Kuppen PJ. Immunological aspects of photodynamic therapy of liver tumors in a rat model for colorectal cancer. Photochem Photobiol. 2003;78: 235-240.
100. Thong PS, Olivo M, Kho KW, et al. Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy. J Environ Pathol Toxicol Oncol. 2008;27:35-42. (Pubitemid 351507421)
101. Friedberg JS, Mick R, Stevenson JP, et al. Phase II trial of pleural photodynamic therapy and surgery for patients with nonsmall-cell lung cancer with pleural spread. J Clin Oncol. 2004;22:2192-2201. (Pubitemid 41095155)
102. Kessel D, Erickson C. Porphyrin photosensitization of multi-drug resistant cell types. Photochem Photobiol. 1992;55: 397-399.
103. Nahabedian MY, Cohen RA, Contino MF, et al. Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. J Natl Cancer Inst. 1988;80:739-743.
104. Sinha AK, Anand S, Ortel BJ, et al. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br J Cancer. 2006;95: 485-495. (Pubitemid 44232558)
105. Ma LW, Berg K, Danielsen HE, Kaalhus O, Iani V, Moan J. Enhanced antitumour effect of photodynamic therapy by microtubule inhibitors. Cancer Lett. 1996;109: 129-139. (Pubitemid 27026213)
106. Mroz P, Hamblin MR. Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model. Proc SPIE. 2009; 7380:73801-73809.
107. Pogue BW, O'Hara JA, Demidenko E, et al. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res. 2003;63: 1025-1033. (Pubitemid 36278434)
108. Luksiene Z, Kalvelyte A, Supino R. On the combination of photodynamic therapy with ionizing radiation. J Photochem Photobiol B. 1999;52:35-42. (Pubitemid 30011493)
109. Weinberg BD, Allison RR, Sibata C, Parent T, Downie G. Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer (NSCLC). Photodiagnosis Photodyn Ther. 2010;7:50-58.
110. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic ther-apy-mediated tumor response. Cancer Res. 2002;62:3956-3961. (Pubitemid 34791059)
111. Makowski M, Grzela T, Niderla J, et al. Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res. 2003;9:5417-5422. (Pubitemid 37413598)
112. Ferrario A, Fisher AM, Rucker N, Gomer CJ. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res. 2005;65:9473-9478. (Pubitemid 41508016)
113. Kleban J, Mikes J, Horvath V, et al. Mechanisms involved in the cell cycle and apoptosis of HT-29 cells pre-treated with MK-886 prior to photodynamic therapy with hypericin. J Photochem Photobiol B. 2008;93:108-118.
114. Sato N, Moore BW, Keevey S, Drazba JA, Hasan T, Maytin EV. Vitamin D enhances ALA-induced protoporphyrin IX production and photodynamic cell death in 3-D organotypic cultures of keratinocytes. J Invest Dermatol. 2007;127:925-934. (Pubitemid 46434641)
115. Liu W, Baer MR, Bowman MJ, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007;13:2463-2470. (Pubitemid 46698598)
116. Biade S, Maziere JC, Mora L, et al. Lovastatin potentiates the photocytotoxic effect of photofrin II delivered to HT29 human colonic adenocarcinoma cells by low density lipoprotein. Photochem Photobiol. 1993;57:371-375.
117. Traul DL, Anderson GS, Bilitz JM, Krieg M, Sieber F. Potentiation of merocyanine 540-mediated photodynamic therapy by salicylate and related drugs. Photochem Photobiol. 1995;62:790-799.
118. Golab J, Olszewska D, Mroz P, et al. Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. Clin Cancer Res. 2002;8:1265-1270. (Pubitemid 34517667)
119. Solar P, Koval J, Mikes J, et al. Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells. Mol Cancer Ther. 2008;7:2263-2271.
120. Huang Z, Chen Q, Shakil A, et al. Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. Photochem Photobiol. 2003;78: 496-502.
121. Matzi V, Maier A, Sankin O, Lindenmann J, Woltsche M, Smolle J, Smolle-Juttner FM. Photodynamic therapy enhanced by hyperbaric oxygenation in palliation of malignant pleural mesothelioma: clinical experience. Photodiagnosis Photodyn Ther. 2004;1:57-64.
122. Orenstein A, Kostenich G, Kopolovic Y, Babushkina T, Malik Z. Enhancement of ALA-PDT damage by IR-induced hyperthermia on a colon carcinoma model. Photochem Photobiol. 1999;69:703-707. (Pubitemid 129548832)
123. Moore JV, West CM, Haylett AK. Vascular function and tissue injury in murine skin following hyperthermia and photodynamic therapy, alone and in combination. Br J Cancer. 1992;66:1037-1043. (Pubitemid 23006139)
124. Nowis D, Legat M, Grzela T, et al. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene. 2006;25:3365-3374. (Pubitemid 43880305)
125. Miyake M, Ishii M, Kawashima K, et al. siRNA-mediated knockdown of the heme synthesis and degradation pathways: modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines. Photochem Photobiol. 2009;85:1020-1027.
126. Curnow A, McIlroy BW, Postle-Hacon MJ, Porter JB, MacRobert AJ, Bown SG. Enhancement of 5-aminolaevulinic acidinduced photodynamic therapy in normal rat colon using hydroxypyridinone ironchelating agents. Br J Cancer. 1998;78: 1278-1282. (Pubitemid 28495237)
127. Henderson BW, Sitnik-Busch TM, Vaughan LA. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent. Photochem Photobiol. 1999;70:64-71. (Pubitemid 129572616)
128. Ferrario A, Rucker N, Wong S, Luna M, Gomer CJ. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res. 2007;67:4989-4995. (Pubitemid 46910208)
129. Jiang F, Robin AM, Katakowski M, et al. Photodynamic therapy with photofrin in combination with Buthionine Sulfoximine (BSO) of human glioma in the nude rat. Lasers Med Sci. 2003;18:128-133. (Pubitemid 37210316)
130. Melnikova VO, Bezdetnaya LN, Brault D, Potapenko AY, Guillemin F. Enhancement of meta-tetrahydroxyphenylchlorin-sensitized photodynamic treatment on human tumor xenografts using a water-soluble vitamin E analogue, Trolox. Int J Cancer. 2000;88:798-803.
131. Ferrario A, Gomer CJ. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol. 2006;25: 251-259. (Pubitemid 43341245)
132. Jiang F, Zhang X, Kalkanis SN, et al. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma. Photochem Photobiol. 2008;84: 128-137. (Pubitemid 350265084)
133. Ferrario A, Chantrain CF, von Tiehl K, et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res. 2004;64:2328-2332. (Pubitemid 38523882)
134. Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y, Hasan T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res. 2006;66:10953-10958. (Pubitemid 44876994)
135. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000; 60:4066-4069. (Pubitemid 30636586)
136. Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol. 2005;56:569-577. (Pubitemid 41425052)
137. Park EK, Bae SM, Kwak SY, et al. Photodynamic therapy with recombinant adenovirus AdmIL-12 enhances anti-tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model. Immunology. 2008;124:461-468. (Pubitemid 351962542)
138. Kessel D. Promotion of PDT efficacy by a Bcl-2 antagonist. Photochem Photobiol. 2008;84:809-814. (Pubitemid 351589364)
139. Kessel D, Caruso JA, Reiners JJ Jr. Potentiation of photodynamic therapy by ursodeoxycholic acid. Cancer Res. 2000;60: 6985-6988. (Pubitemid 32059173)
140. Separovic D, Bielawski J, Pierce JS, et al. Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas. Br J Cancer. 2009;100: 626-632.
141. Weyergang A, Berg K, Kaalhus O, Peng Q, Selbo PK. Photodynamic therapy targets the mTOR signaling network in vitro and in vivo. Mol Pharm. 2009;6:255-264.
142. Peng Q, Warloe T, Moan J, et al. Antitumor effect of 5-aminolevulinic acidmediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res. 2001;61:5824-5832. (Pubitemid 32769101)
143. Cincotta L, Szeto D, Lampros E, Hasan T, Cincotta AH. Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Photochem Photobiol. 1996;63:229-237.
144. van Geel IP, Oppelaar H, Oussoren YG, Schuitmaker JJ, Stewart FA. Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C. Br J Cancer. 1995;72:344-350.
145. Berg K, Anholt H, Bech O, Moan J. The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br J Cancer. 1996;74:688-697. (Pubitemid 26300758)
146. Rasheva VI, Domingos PM. Cellular responses to endoplasmic reticulum stress and apoptosis. Apoptosis. 2009;14: 996-1007.
147. Bhuvaneswari R, Yuen GY, Chee SK, Olivo M. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochem Photobiol Sci. 2007;6:1275-1283. (Pubitemid 350191102)
148. Cengel KA, Hahn SM, Glatstein E. C225 and PDT combination therapy for ovarian cancer: the play's the thing. J Natl Cancer Inst. 2005;97:1488-1489. (Pubitemid 41631941)
149. Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol. 1976;115:150-151.
150. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978;38: 2628-2635. (Pubitemid 8390848)
151. Fayter D, Corbett M, Heirs M, Fox D, Eastwood A. A systematic review of photodynamic therapy in the treatment of precancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess. 2010;14: 1-288.
152. Gao F, Bai Y, Ma SR, Liu F, Li ZS. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17:125-131.
153. Hahn SM, Smith RP, Friedberg J. Photodynamic therapy for mesothelioma. Curr Treat Options Oncol. 2001;2:375-383.
154. Hahn SM, Fraker DL, Mick R, et al. A phase II trial of intraperitoneal photody-namic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res. 2006;12:2517-2525.
155. Hendren SK, Hahn SM, Spitz FR, et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol. 2001;8:65-71. (Pubitemid 32126826)
156. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56:125-143. (Pubitemid 44969292)
157. Nestor MS, Gold MH, Kauvar AN, et al. The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol. 2006;5:140-154.
158. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6:143-148.
159. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140:41-46. (Pubitemid 38090269)
160. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14:99-106. (Pubitemid 36648700)
161. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48:227-232. (Pubitemid 36232321)
162. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol. 2006;142:729-735.
163. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol. 2002;47:258-262.
164. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol. 1999;41(3 pt 1):414-418. (Pubitemid 29418508)
165. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2:629-635.
166. Szeimies RM, Stockfleth E, Popp G, et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol. 2010;162:410-414.
167. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol. 1996;135:766-771. (Pubitemid 26375895)
168. Morton CA. Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol Clin. 2007;25:81-87. (Pubitemid 44780063)
169. Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol. 2003;148:539-543. (Pubitemid 36461334)
170. Taub AF. Photodynamic therapy: other uses. Dermatol Clin. 2007;25:101-109. (Pubitemid 44780061)
171. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? J Am Acad Dermatol. 1993;28:17-21. (Pubitemid 23019558)
172. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer. 1994;69:605-608. (Pubitemid 24076490)
173. Zeitouni NC, Shieh S, Oseroff AR. Laser and photodynamic therapy in the management of cutaneous malignancies. Clin Dermatol. 2001;19:328-338. (Pubitemid 32672898)
174. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18:547-553.
175. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol. 2008;22:1302-1311.
176. Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acidphotodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol. 2008;159: 864-870.
177. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140:17-23. (Pubitemid 38090266)
178. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143:1131-1136. (Pubitemid 47443364)
179. Berroeta L, Clark C, Dawe RS, Ibbotson SH, Fleming CJ. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol. 2007; 157:401-403. (Pubitemid 47083846)
180. Jerjes W, Upile T, Akram S, Hopper C. The surgical palliation of advanced head and neck cancer using photodynamic therapy. Clin Oncol (R Coll Radiol). 2010;22: 785-791.
181. Bredell MG, Besic E, Maake C, Walt H. The application and challenges of clinical PD-PDT in the head and neck region: a short review. J Photochem Photobiol B. 2010;101:185-190.
182. Li LB, Luo RC, Liao WJ, Zhang MJ, Luo YL, Miao JX. Clinical study of Photofrin photodynamic therapy for the treatment of relapse nasopharyngeal carcinoma. Photochem Photobiol Ther. 2006;3:266-271.
183. Biel MA. Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope. 1998;108:1259-1268.
184. Biel M. Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med. 2006;38: 349-355.
185. Keller GS, Doiron DR, Fisher GU. Photodynamic therapy in otolaryngology-head and neck surgery. Arch Otolaryngol. 1985;111: 758-761. (Pubitemid 16195508)
186. Feyh J, Goetz A, Muller W, Konigsberger R, Kastenbauer E. Photodynamic therapy in head and neck surgery. J Photochem Photobiol B. 1990;7:353-358.
187. Feyh J, Gutmann A, Leunig A. A photodynamic therapy in head and neck surgery. Laryngol Rhinol Otol. 1993;72:273-278. (Pubitemid 23195296)
188. Hopper C, Kubler A, Lewis H, Tan IB, Putnam G. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer. 2004;111:138-146. (Pubitemid 38859295)
189. Fan KF, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer. 1996;78: 1374-1383. (Pubitemid 26317856)
190. Copper MP, Triesscheijn M, Tan IB, Ruevekamp MC, Stewart FA. Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx. Clin Otolaryngol. 2007;32:185-189. (Pubitemid 46872821)
191. D'Cruz AK, Robinson MH, Biel MA. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. Head Neck. 2004;26:232-240. (Pubitemid 38292733)
192. Grant WE, Hopper C, MacRobert AJ, Speight PM, Bown SG. Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid. Lancet. 1993;342:147-148. (Pubitemid 23200442)
193. Sieron A, Namyslowski G, Misiolek M, Adamek M, Kawczyk-Krupka A. Photodynamic therapy of premalignant lesions and local recurrence of laryngeal and hypopharyngeal cancers. Eur Arch Otorhinolaryngol. 2001;258:349-352. (Pubitemid 32930194)
194. Wolfsen HC. Carpe luz-seize the light: endoprevention of esophageal adenocarcinoma when using photodynamic therapy with porfimer sodium. Gastrointest Endosc. 2005;62:499-503. (Pubitemid 41383766)
195. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144: 832-840. (Pubitemid 32374789)
196. Hahn S, Glatstein E. The emergence of photodynamic therapy as a major modality in cancer treatment. Rev Contemp Pharmocother. 1999;10:69-74. (Pubitemid 29195070)
197. Wolfsen HC, Hemminger LL, Wallace MB, Devault KR. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther. 2004;20:1125-1131. (Pubitemid 39657946)
198. Corti L, Skarlatos J, Boso C, et al. Outcome of patients receiving photodynamic therapy for early esophageal cancer. Int J Radiat Oncol Biol Phys. 2000;47:419-424. (Pubitemid 30236384)
199. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007;66:460-468. (Pubitemid 47304412)
200. Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev. 2010;(1): CD004060.
201. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488-498. (Pubitemid 41383764)
202. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut. 2004;53:1736-1744. (Pubitemid 39556888)
203. Mackenzie GD, Jamieson NF, Novelli MR, et al. How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of highgrade dysplasia in Barrett's esophagus. Lasers Med Sci. 2008;23:203-210. (Pubitemid 351422641)
204. Wolfsen HC. Uses of photodynamic therapy in premalignant and malignant lesions of the gastrointestinal tract beyond the esophagus. J Clin Gastroenterol. 2005; 39:653-664. (Pubitemid 41177082)
205. Nakamura H, Yanai H, Nishikawa J, et al. Experience with photodynamic therapy (endoscopic laser therapy) for the treatment of early gastric cancer. Hepatogastroenterology. 2001;48:1599-1603. (Pubitemid 34003485)
206. Yanai H, Kuroiwa Y, Shimizu N, et al. The pilot experience of immunotherapycombined photodynamic therapy for advanced gastric cancer in elderly patients. Int J Gastrointest Cancer. 2002; 32:139-142. (Pubitemid 36749002)
207. Mlkvy P, Messmann H, Debinski H, et al. Photodynamic therapy for polyps in familial adenomatous polyposis-a pilot study. Eur J Cancer. 1995;31A:1160-1165.
208. Abulafi AM, Allardice JT, Williams NS, van Someren N, Swain CP, Ainley C. Photodynamic therapy for malignant tumours of the ampulla of Vater. Gut. 1995;36: 853-856.
209. McCaughan JS Jr, Mertens BF, Cho C, Barabash RD, Payton HW. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg. 1991;126:111-113.
210. Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology. 1998;114:536-542.
211. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003; 125:1355-1363. (Pubitemid 37409755)
212. Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244: 230-239. (Pubitemid 44305537)
213. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100:2426-2430.
214. Pereira SP, Ayaru L, Rogowska A, Mosse A, Hatfield AR, Bown SG. Photodynamic therapy of malignant biliary strictures using meso- tetrahydroxyphenylchlorin. Eur J Gastroenterol Hepatol. 2007;19: 479-485. (Pubitemid 46725754)
215. Bown SG, Rogowska AZ, Whitelaw DE, et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50:549-557. (Pubitemid 34638877)
216. Loh CS, Bliss P, Bown SG, Krasner N. Photodynamic therapy for villous adenomas of the colon and rectum. Endoscopy. 1994; 26:243-246. (Pubitemid 24104979)
217. Nakamura T, Fukui H, Ishii Y, Ejiri K, Ejiri M. Photodynamic therapy with polypectomy for rectal cancer. Gastrointest Endosc. 2003;57:266-269. (Pubitemid 36236777)
218. Spinelli P, Mancini A, Dal Fante M. Endoscopic treatment of gastrointestinal tumors: indications and results of laser photocoagulation and photodynamic therapy. Semin Surg Oncol. 1995;11:307-318.
219. Abulafi AM, Dejode M, Allardice JT, Ansell J, Rogers J, Williams NS. Adjuvant intraoperative photodynamic therapy in experimental colorectal cancer. Br J Surg. 1995;82:178-181.
220. Wang S, Bromley E, Xu L, Chen JC, Keltner L. Talaporfin sodium. Expert Opin Pharmacother. 2010;11:133-140.
221. Cengel KA, Glatstein E, Hahn SM. Intraperitoneal photodynamic therapy. Cancer Treat Res. 2007;134:493-514.
222. Hahn SM, Putt ME, Metz J, et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res. 2006;12: 5464-5470. (Pubitemid 44497262)
223. Wilson JJ, Jones H, Burock M, et al. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int J Oncol. 2004;24:711-717.
224. Nathan TR, Whitelaw DE, Chang SC, et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol. 2002;168:1427-1432. (Pubitemid 35034139)
225. Moore CM, Nathan TR, Lees WR, et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med. 2006;38: 356-363.
226. Du KL, Mick R, Busch TM, et al. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med. 2006;38:427-434.
227. Patel H, Mick R, Finlay J, et al. Motexafin lutetium-photodynamic therapy of prostate cancer: short-and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008;14:4869-4876.
228. Weersink RA, Forbes J, Bisland S, et al. Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol. 2005;81:106-113. (Pubitemid 40327566)
229. Trachtenberg J, Bogaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol. 2007;178: 1974-1979; discussion 1979. (Pubitemid 47554440)
230. Trachtenberg J, Weersink RA, Davidson SR, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008;102: 556-562.
231. Prout GR Jr, Lin CW, Benson R Jr, et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N Engl J Med. 1987;317: 1251-1255. (Pubitemid 17147966)
232. Uchibayashi T, Koshida K, Kunimi K, Hisazumi H. Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder. Br J Cancer. 1995;71: 625-628.
233. D'Hallewin MA, Baert L. Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder. Urology. 1995;45:763-767.
234. Nseyo UO, Shumaker B, Klein EA, Sutherland K. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. J Urol. 1998;160:39-44. (Pubitemid 29479411)
235. Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology. 2003;61:338-341. (Pubitemid 36206528)
236. Waidelich R, Beyer W, Knuchel R, et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology. 2003;61:332-337. (Pubitemid 36206527)
237. Jocham D, von Wietersheim J, Pfluger H, et al. BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study [in German]. Aktuelle Urol. 2009;40: 91-99.
238. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol. 2006;175: 1201-1207.
239. Skyrme RJ, French AJ, Datta SN, Allman R, Mason MD, Matthews PN. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. BJU Int. 2005;95: 1206-1210. (Pubitemid 40799431)
240. Hayata Y, Kato H, Konaka C, Ono J, Takizawa N. Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer. Chest. 1982;81:269-277. (Pubitemid 12191939)
241. LoCicero J 3rd, Metzdorff M, Almgren C. Photodynamic therapy in the palliation of late stage obstructing non-small cell lung cancer. Chest. 1990;98:97-100. (Pubitemid 20223672)
242. Moghissi K, Dixon K, Stringer M, Freeman T, Thorpe A, Brown S. The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur J Cardiothorac Surg. 1999;15:1-6. (Pubitemid 29084543)
243. Diaz-Jimenez JP, Martinez-Ballarin JE, Llunell A, Farrero E, Rodriguez A, Castro MJ. Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. Eur Respir J. 1999;14:800-805. (Pubitemid 29519340)
244. McCaughan JS Jr, Williams TE. Photodynamic therapy for endobronchial malignant disease: a prospective fourteen-year study. J Thorac Cardiovasc Surg. 1997; 114:940-946; discussion 946-947.
245. Furuse K, Fukuoka M, Kato H, et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol. 1993;11: 1852-1857. (Pubitemid 23304607)
246. Lam S, Muller NL, Miller RR, et al. Laser treatment of obstructive endobronchial tumors: factors which determine response. Lasers Surg Med. 1987;7:29-35. (Pubitemid 17038842)
247. Loewen GM, Pandey R, Bellnier D, Henderson B, Dougherty T. Endobronchial photodynamic therapy for lung cancer. Lasers Surg Med. 2006;38:364-370.
248. Corti L, Toniolo L, Boso C, et al. Longterm survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers Surg Med. 2007;39:394-402. (Pubitemid 47041088)
249. Endo C, Miyamoto A, Sakurada A, et al. Results of long-term follow-up of photodynamic therapy for roentgenographically occult bronchogenic squamous cell carcinoma. Chest. 2009;136:369-375.
250. Usuda J, Ichinose S, Ishizumi T, et al. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways 1.0 cm in diameter. Clin Cancer Res. 2010;16:2198-2204.
251. Minnich DJ, Bryant AS, Dooley A, Cerfolio RJ. Photodynamic laser therapy for lesions in the airway. Ann Thorac Surg. 2010;89: 1744-1748; discussion 1748-1749.
252. Friedberg JS. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:177-187.
253. Moskal TL, Dougherty TJ, Urschel JD, et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg. 1998;66: 1128-1133. (Pubitemid 28518037)
254. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 1997;4:628-633. (Pubitemid 127725490)
255. Friedberg JS, Mick R, Stevenson J, et al. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg. 2003;75:952-959. (Pubitemid 36298375)
256. Schouwink H, Rutgers ET, van der Sijp J, et al. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest. 2001;120:1167-1174. (Pubitemid 32960089)
257. Friedberg JS, Cengel KA. Pleural malignancies. Semin Radiat Oncol. 2010;20: 208-214.
258. Kostron H. Photodynamic diagnosis and therapy and the brain. Methods Mol Biol. 2010;635:261-280.
259. Perria C, Capuzzo T, Cavagnaro G, et al. Fast attempts at the photodynamic treatment of human gliomas. J Neurosurg Sci. 1980;24:119-129. (Pubitemid 11125190)
260. Kaye AH, Morstyn G, Brownbill D. Adjuvant high-dose photoradiation therapy in the treatment of cerebral glioma: a phase 1-2 study. J Neurosurg. 1987;67:500-505. (Pubitemid 17145749)
261. Muller PJ, Wilson BC. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol. 1995;11:346-354.
262. Krishnamurthy S, Powers SK, Witmer P, Brown T. Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors. Lasers Surg Med. 2000;27:224-234.
263. Kostron H, Fritsch E, Grunert V. Photodynamic therapy of malignant brain tumours: a phase I/II trial. Br J Neurosurg. 1988;2:241-248.
264. Marks PV, Belchetz PE, Saxena A, et al. Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial-an early report. Br J Neurosurg. 2000;14:317-325.
265. Eljamel S. Photodynamic assisted surgical resection and treatment of malignant brain tumors; technique, technology and clinical application. Photodiag Photodyn Ther. 2004;1:93-98.
266. Muller P, Wilson B. Photodynamic therapy of brain tumours-post-operative "field fractionation." J Photochem Photobiol B. 1991;9:117-119.
267. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg. 2000;93: 1003-1013. (Pubitemid 32800611)
268. Stylli SS, Kaye AH, MacGregor L, Howes M, Rajendra P. Photodynamic therapy of high grade glioma-long term survival. J Clin Neurosci. 2005;12:389-398. (Pubitemid 40745222)
269. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7:392-401.
270. Muller PJ, Wilson BC. Photodynamic therapy of brain tumors-a work in progress. Lasers Surg Med. 2006;38:384-389.
271. Eljamel MS, Goodman C, Moseley H. ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci. 2008;23:361-367.
272. von Tappeiner H, Jesionek A. Therapeutische Versuche mit fluoreszierenden Stoffen. Mü nch Med Wochenschr. 1903;47: 2042-2044.
273. Starkey JR, Rebane AK, Drobizhev MA, et al. New two-photon activated photodynamic therapy sensitizers induce xenograft tumor regressions after near-IR laser treatment through the body of the host mouse. Clin Cancer Res. 2008;14: 6564-6573.
274. Collins HA, Khurana M, Moriyama EH, et al. Blood vessel closure using photosensitisers engineered for two-photon excitation. Nature Photonics. 2008;2:420-424.
275. Lilge L, Portnoy M, Wilson BC. Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue. Br J Cancer. 2000;83:1110-1117.
276. Mathews MS, Angell-Petersen E, Sanchez R, et al. The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids. Lasers Surg Med. 2009;41:578-584.
277. Davies N, Wilson BC. Interstitial in vivo ALA-PpIX mediated metronomic photodynamic therapy (mPDT) using the CNS-1 astrocytoma with bioluminescence monitoring. Photodiag Photodyn Ther. 2007;4: 202-212. (Pubitemid 47239507)
278. Alqawi O, Espiritu M, Singh G. Molecular mechanisms associated with ALA-PDT of brain tumor cells. Proc SPIE. 2009;7380: 73806Y.1-73806Y.11.
279. Chen J, Stefflova K, Niedre MJ, et al. Protease-triggered photosensitizing beacon based on singlet oxygen quenching and activation. J Am Chem Soc. 2004;126: 11450-11451. (Pubitemid 39244956)
280. Zheng G, Chen J, Stefflova K, Jarvi M, Li H, Wilson BC. Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci USA. 2007;104:8989-8994. (Pubitemid 47175424)
281. Chen J, Lovell JF, Lo PC, et al. A tumor mRNA-triggered photodynamic molecular beacon based on oligonucleotide hairpin control of singlet oxygen production. Photochem Photobiol Sci. 2008;7:775-781. (Pubitemid 351931552)
282. Chen J, Liu TWB, Lo P-C, Wilson BC, Zheng G. "Zipper" molecular beacons: A generalized strategy to optimize the performance of activatable protease probes. Bioconj Chem. 2009;20:1836-1842.
283. Wilson BC. Photonic and non-photonic based nanoparticles in cancer imaging and therapeutics. In: Dubowski J, Tanev S, eds. Photon-Based Nanoscience and Nanobiotechnology. Dordrecht, the Netherlands: Springer; 2006:121-151.
284. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol. 1993;57:1000-1006.
285. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60:1627-1637.
286. Kim S, Ohulchanskyy TY, Pudavar HE, Pandey RK, Prasad PN. Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregationenhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc. 2007;129:2669-2675. (Pubitemid 46364075)
287. Rai P, Chang SK, Mai Z, Neuman D, Hasan T. Nanotechnology-based combination therapy improves treatment response in cancer models. Proc SPIE. 2009;7380: 73801-73811.
288. Berg K, Selbo PK, Prasmickaite L, et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 1999;59: 1180-1183. (Pubitemid 29136242)
289. Norum OJ, Selbo PK, Weyergang A, Giercksky KE, Berg K. Photochemical internalization (PCI) in cancer therapy: from bench towards bedside medicine. J Photochem Photobiol B. 2009;96:83-92.
290. Selbo PK, Rosenblum MG, Cheung LH, Zhang W, Berg K. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel. PLoS One. 2009;4:e6691.